Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SAE1 | Q9UBE0 | 20/20 | 0.49 |
| ▸ | UBA2 | Q9UBT2 | 20/20 | 0.49 |
| ▸ | NAE1 | Q13564 | 14/20 | 0.49 |
| ▸ | UBA3 | Q8TBC4 | 14/20 | 0.49 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17429143 | 0.92 | SAE1 (0.52) | SAE1UBA2NAE1UBA3 | |
| SCHEMBL17429071 | 0.89 | SAE1 (0.48) | SAE1UBA2NAE1UBA3 | |
| SCHEMBL17429100 | 0.88 | SAE1 (0.51) | SAE1UBA2NAE1UBA3 | |
| SCHEMBL17429092 | 0.87 | SAE1 (0.45) | SAE1UBA2NAE1UBA3 | |
| SCHEMBL17429153 | 0.86 | SAE1 (0.55) | SAE1UBA2NAE1UBA3CA1 | |
| SCHEMBL17429149 | 0.86 | SAE1 (0.49) | SAE1UBA2NAE1UBA3 | |
| SCHEMBL17429072 | 0.86 | SAE1 (0.44) | SAE1UBA2NAE1UBA3 | |
| SCHEMBL17429039 | 0.86 | SAE1 (0.48) | SAE1UBA2NAE1UBA3 | |
| SCHEMBL17429146 | 0.85 | SAE1 (0.49) | SAE1UBA2NAE1UBA3 | |
| SCHEMBL17421341 | 0.85 | SAE1 (0.47) | SAE1UBA2NAE1UBA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230293522-A1 | HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF SUMO ACTIVATING ENZYME | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-09-21 | — | — | US | disclosed |
| US-20170216290-A1 | HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF SUMO ACTIVATING ENZYME | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2017-08-03 | — | — | US | disclosed |
| US-9683003-B2 | Heteroaryl compounds useful as inhibitors of SUMO activating enzyme | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2017-06-20 | — | — | US | disclosed |
| US-20170002032-A9 | HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF SUMO ACTIVATING ENZYME | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2017-01-05 | — | — | US | disclosed |
| US-20160009744-A1 | HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF SUMO ACTIVATING ENZYME | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2016-01-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170002032-A9 | HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF SUMO ACTIVATING ENZYME | SAE1, SUMO1, SUMO3 | SAE1 1/4885UBA2 5/4885NAE1 88/4885 |
| US-20230293522-A1 | HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF SUMO ACTIVATING ENZYME | SAE1, SUMO1, SUMO3 | SAE1 1/4885UBA2 5/4885NAE1 88/4885 |
| US-20170216290-A1 | HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF SUMO ACTIVATING ENZYME | SAE1, SUMO1, SUMO3 | SAE1 1/4885UBA2 5/4885NAE1 88/4885 |
| US-20160009744-A1 | HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF SUMO ACTIVATING ENZYME | SAE1, SUMO1, SUMO3 | SAE1 1/4885UBA2 5/4885NAE1 88/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.